TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Adolescents With Anorexia Nervosa
Brief Summary: This study will compare the effectiveness of family-based therapy versus individual psychotherapy for the treatment of adolescent anorexia nervosa.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Family Based Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ego-Oriented Individual Psychotherapy | Intervention Type: BEHAVIORAL; Name: Family Based Therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Ego-Oriented Individual Psychotherapy; Assigned to Arm(s): 2
B: Arm Label: Family Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Family Behavior Therapy | Arm Label: Systems Family Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Systems Family Therapy | Intervention Type: BEHAVIORAL; Name: Family Behavior Therapy; Assigned to Arm(s): Family Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Systems Family Therapy; Assigned to Arm(s): Systems Family Therapy
C: Arm Label: Exposure and Response Prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP) | Arm Label: Cognitive Behavior Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive behavioral therapy (CBT) | Intervention Type: BEHAVIORAL; Name: Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP); Assigned to Arm(s): Exposure and Response Prevention | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): Cognitive Behavior Therapy
D: Arm Label: Cognitive behavioral counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Identity Intervention Program | Arm Label: Supportive therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Psychotherapy for the Eating Disorders | Intervention Type: BEHAVIORAL; Name: Identity Intervention Program; Assigned to Arm(s): Cognitive behavioral counseling | Intervention Type: BEHAVIORAL; Name: Supportive Psychotherapy for the Eating Disorders; Assigned to Arm(s): Supportive therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Oral Sucrose Analgesia During Routine Immunizations at 6 Weeks and 4 Months of Age
Brief Summary: The study explores the potential benefits of a sugar water solution for decreasing pain in infants during routine immunizations.


Options:
A: Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): N/A
B: Arm Label: Noanalgesia; Type: SHAM_COMPARATOR; Interventions: Procedure: Water 2mL PO 2 minutes prior to intra-muscular injection | Arm Label: Skin-to-skin; Type: EXPERIMENTAL; Interventions: Procedure: skin-to-skin contact | Arm Label: Glucose; Type: EXPERIMENTAL; Interventions: Procedure: Glucose 25% 2 mL PO 2 minutes prior to injection | Arm Label: Skin&Glucose; Type: EXPERIMENTAL; Interventions: Procedure: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards. | Intervention Type: PROCEDURE; Name: Water 2mL PO 2 minutes prior to intra-muscular injection; Assigned to Arm(s): Noanalgesia | Intervention Type: PROCEDURE; Name: skin-to-skin contact; Assigned to Arm(s): Skin-to-skin | Intervention Type: PROCEDURE; Name: Glucose 25% 2 mL PO 2 minutes prior to injection; Assigned to Arm(s): Glucose | Intervention Type: PROCEDURE; Name: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.; Assigned to Arm(s): Skin&Glucose
C: Intervention Type: DRUG; Name: Sucrose solution 30%1 ml; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Sucrose; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation
Brief Summary: The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051019


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): nicotine
C: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation
Brief Summary: The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051019


Options:
A: Arm Label: Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Behavioral: Behavioural support | Arm Label: Patch and nicotine-free e-cigarette; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Device: e-cigarette, Behavioral: Behavioural support | Arm Label: Patch and nicotine e-cigarette; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Device: e-cigarette, Drug: Nicotine, Behavioral: Behavioural support | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): Patch, Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette | Intervention Type: DEVICE; Name: e-cigarette; Assigned to Arm(s): Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette | Intervention Type: DRUG; Name: Nicotine; Assigned to Arm(s): Patch and nicotine e-cigarette | Intervention Type: BEHAVIORAL; Name: Behavioural support; Assigned to Arm(s): Patch, Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette
B: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: ENDS (vaporizer/e-cig) and smoking cessation counseling | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Smoking cessation counseling | Intervention Type: OTHER; Name: ENDS (vaporizer/e-cig) and smoking cessation counseling; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Smoking cessation counseling; Assigned to Arm(s): Control group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation
Brief Summary: The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051019


Options:
A: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
B: Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation
Brief Summary: The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051019


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone, Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1, 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch
D: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation
Brief Summary: The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051019


Options:
A: Arm Label: varenicline with counselling; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo with counselling; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline with counselling | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo with counselling
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychological advice, Drug: Bupropion Pill, Drug: Varenicline Pill | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: So-Lo-Mo, Behavioral: Psychological advice, Drug: Bupropion Pill, Drug: Varenicline Pill | Intervention Type: OTHER; Name: So-Lo-Mo; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Psychological advice; Assigned to Arm(s): Control, Intervention | Intervention Type: DRUG; Name: Bupropion Pill; Assigned to Arm(s): Control, Intervention | Intervention Type: DRUG; Name: Varenicline Pill; Assigned to Arm(s): Control, Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation
Brief Summary: The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051019


Options:
A: Arm Label: Extended Brief Contact; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Check-ins with medical staff | Arm Label: Extended Health Education; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Health Model | Arm Label: Extended Relapse Prevention plus varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Relapse Prevention Model | Arm Label: Extended Relapse Prevention; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Relapse Prevention Model | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Extended Brief Contact, Extended Health Education, Extended Relapse Prevention, Extended Relapse Prevention plus varenicline | Intervention Type: BEHAVIORAL; Name: Initial Individual counseling; Assigned to Arm(s): Extended Brief Contact, Extended Health Education, Extended Relapse Prevention, Extended Relapse Prevention plus varenicline | Intervention Type: BEHAVIORAL; Name: Check-ins with medical staff; Assigned to Arm(s): Extended Brief Contact | Intervention Type: BEHAVIORAL; Name: Extended Individual Counseling - Health Model; Assigned to Arm(s): Extended Health Education | Intervention Type: BEHAVIORAL; Name: Extended Individual Counseling - Relapse Prevention Model; Assigned to Arm(s): Extended Relapse Prevention, Extended Relapse Prevention plus varenicline
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
D: Arm Label: Chantix (varenicline); Type: EXPERIMENTAL; Interventions: Drug: Chantix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix (varenicline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation
Brief Summary: The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051019


Options:
A: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: 1 Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation
Brief Summary: The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051019


Options:
A: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Dose adjustment of nicotine replacement therapies | Arm Label: 2; Type: OTHER; Interventions: Drug: nicotine patch | Intervention Type: PROCEDURE; Name: Dose adjustment of nicotine replacement therapies; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): 2
D: Arm Label: Selegiline Transdermal Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Selegiline Transdermal Patch, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Selegiline Transdermal Patch; Assigned to Arm(s): Selegiline Transdermal Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Placebo, Selegiline Transdermal Patch

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation
Brief Summary: The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051019


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Behavioral group smoking cessation treatment | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Behavioral group smoking cessation treatment, Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral group smoking cessation treatment; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nortriptyline | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: transdermal nicotine | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: transdermal nicotine; Assigned to Arm(s): 2
D: Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Placebo | Arm Label: Experimental: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Varenicline | Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling; Assigned to Arm(s): Experimental: Varenicline, Placebo Control | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Control | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Experimental: Varenicline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation
Brief Summary: The purpose of the study was to measure the safety and efficacy of a 12-week flexible dosing strategy of CP-526,555 compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051019


Options:
A: Arm Label: Effectiveness of Nicotine patch only; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Effectiveness of Combination NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine lozenge, Drug: Nicotine Patch | Arm Label: Effectiveness of Varenicline [Chantix]; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Effectiveness of Varenicline [Chantix] | Intervention Type: DRUG; Name: Nicotine lozenge; Assigned to Arm(s): Effectiveness of Combination NRT | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Effectiveness of Combination NRT, Effectiveness of Nicotine patch only
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A

Answer: C